-
公开(公告)号:US10995089B2
公开(公告)日:2021-05-04
申请号:US15777386
申请日:2016-11-17
申请人: AGV Discovery ENSCM , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Universite de Montpellier
发明人: Jean-François Guichou , Cédric Bories , Clément Geoffroy , Charline Duquenne , Muriel Gelin , Gilles Labesse , Yannick Bessin , Loic Mathieu
IPC分类号: C07D471/04 , A61P35/00 , C07D519/00 , C07F9/6561 , C07D491/048 , C07D491/107 , C07D491/113
摘要: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
-
公开(公告)号:US11708364B2
公开(公告)日:2023-07-25
申请号:US17216114
申请日:2021-03-29
申请人: AGV Discovery , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Universite De Montpellier
发明人: Jean-François Guichou , Cédric Bories , Clément Geoffroy , Charline Duquenne , Muriel Gelin , Gilles Labesse , Yannick Bessin , Loic Mathieu
IPC分类号: A61K31/4353 , C07D471/04 , A61P35/00 , C07D519/00 , C07F9/6561 , C07D491/048 , C07D491/113 , C07D491/107
CPC分类号: C07D471/04 , A61K31/4353 , A61P35/00 , C07D491/048 , C07D491/107 , C07D491/113 , C07D519/00 , C07F9/6561
摘要: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
-
公开(公告)号:US11827637B2
公开(公告)日:2023-11-28
申请号:US18096996
申请日:2023-01-13
申请人: AGV Discovery , Institut National de la Sante et de la Recherche Medicale (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , Universite De Montpellier
IPC分类号: C07D413/14 , A61K31/5377 , C07D471/04 , C07D213/643 , C07F5/02
CPC分类号: C07D471/04 , C07D213/643 , C07F5/027
摘要: The present invention concerns a compound of formula (I):
or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
-
-